Ligand validation:5T0L

CB3: 10-PROPARGYL-5,8-DIDEAZAFOLIC ACID

CB3 is a Ligand Of Interest in 5T0L designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5T0L_CB3_A_703	7%	18%	0.354	0.815	1.18	2.31	3	8	3	0	100%	0.5
5T0L_CB3_B_703	6%	19%	0.361	0.801	1.18	2.25	3	8	8	0	100%	0.5
4EIL_CB3_G_702	76%	9%	0.105	0.941	1.96	2.43	8	13	1	0	100%	1
6AOH_CB3_B_703	21%	17%	0.297	0.91	1.18	2.4	3	8	1	0	100%	0.5
6N1T_CB3_B_703	21%	17%	0.297	0.91	1.18	2.4	3	8	1	0	100%	0.5
6N1S_CB3_A_703	17%	33%	0.303	0.88	0.76	1.88	1	5	0	0	100%	0.5
6AOI_CB3_B_703	10%	17%	0.362	0.869	1.16	2.39	2	10	1	0	100%	0.5
4GEV_CB3_A_702	96%	26%	0.058	0.966	1.18	1.82	3	8	0	0	100%	1
6NNR_CB3_B_302	93%	19%	0.076	0.97	1.19	2.25	3	8	0	0	100%	1
2AAZ_CB3_E_2551	92%	5%	0.081	0.973	2.5	2.75	16	15	0	0	100%	0.25
2FTO_CB3_X_266	82%	17%	0.087	0.943	1.58	2	6	6	1	0	100%	1
6CDZ_CB3_A_701	53%	20%	0.16	0.922	1.31	2.06	3	11	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.